VIGL

Vigil Neuroscience, Inc.

A clinical-stage biotech company working on medicines for rare and common diseases of the brain and nervous system, built around the biology of microglia — the brain's own immune cells. Its drug candidates, such as VGL101, target a protein on microglia to treat conditions like adult-onset leukoencephalopathy. Founded in 2020 by scientists and backed by Versant Ventures, the name "Vigil" reflects the idea of keeping watch over the brain's health.